At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KURE KraneShares MSCI All China Health Care Index ETF
Market Closed 10-02 16:00:00 EDT
19.14
-0.21
-1.08%
盘后19.14
+0.000.00%
19:30 EDT
High19.20Low18.87Vol127.96K
Open19.04D1 Closing19.35Amplitude1.71%
Mkt Cap112.91MTradable Cap112.91MTotal Shares5.90M
T/O2.44MT/O Rate2.17%Tradable Shares5.90M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  10-02 17:50
Major Drugmakers Turn to China for Licensing Deals
Wuxi Biologics (Cayman) Stock Slides 2.7% in Hong Kong
Dow Jones  ·  10-02 16:32
Wuxi Biologics (Cayman) Stock Slides 2.7% in Hong Kong
Akeso (SEHK:9926) Could Be 31% Undervalued As Phase III Trial Hits Key Goals
Simply Wall St.  ·  10-02 15:18
Akeso (SEHK:9926) Could Be 31% Undervalued As Phase III Trial Hits Key Goals
CSPC Pharmaceutical Group (SEHK:1093) Could Be 26% Undervalued Following Three Phase III Updates
Simply Wall St.  ·  10-01
CSPC Pharmaceutical Group (SEHK:1093) Could Be 26% Undervalued Following Three Phase III Updates
CSPC Reports Blood Sugar Reduction in Phase III Diabetes Study
MT Newswires Live  ·  10-01
CSPC Reports Blood Sugar Reduction in Phase III Diabetes Study
What IBI3003 Trial Progress Means For Innovent Biologics Stock
Simply Wall St.  ·  10-01
What IBI3003 Trial Progress Means For Innovent Biologics Stock
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  09-30
Major Drugmakers Turn to China for Licensing Deals
CSPC Pharmaceutical (01093) Reveals Positive Phase III Results for Edaglutide Alfa Injection Combined with Metformin in Chinese Adults with Type 2 Diabetes at EASD 2026
Stock News  ·  09-30
CSPC Pharmaceutical (01093) Reveals Positive Phase III Results for Edaglutide Alfa Injection Combined with Metformin in Chinese Adults with Type 2 Diabetes at EASD 2026
Should Phase III Cancer Trial Win Require Action From Akeso Stock Investors?
Simply Wall St.  ·  09-30
Should Phase III Cancer Trial Win Require Action From Akeso Stock Investors?
CSPC Pharmaceutical Group Stock Rallies 6.3% in Hong Kong, Outperforms Competitors
Dow Jones  ·  09-30
CSPC Pharmaceutical Group Stock Rallies 6.3% in Hong Kong, Outperforms Competitors
Wuxi Biologics (Cayman) Stock Rises 4.8% in Hong Kong
Dow Jones  ·  09-30
Wuxi Biologics (Cayman) Stock Rises 4.8% in Hong Kong
Goldman Sachs: Asian CDMOs Enter a Structural Growth Cycle, with Peptides, ADCs, Oligonucleotides, and AIDD as New Engines
Stock News  ·  09-30
Goldman Sachs: Asian CDMOs Enter a Structural Growth Cycle, with Peptides, ADCs, Oligonucleotides, and AIDD as New Engines
Daiwa: Akeso's Global Partner Summit Secures AstraZeneca Investment, Boosting Ivonescimab's Global Peak Sales Potential
Stock News  ·  09-30
Daiwa: Akeso's Global Partner Summit Secures AstraZeneca Investment, Boosting Ivonescimab's Global Peak Sales Potential
Nomura Assigns HK$138.29 Target Price and "Buy" Rating to Akeso
Stock News  ·  09-30
Nomura Assigns HK$138.29 Target Price and "Buy" Rating to Akeso
AI Drug Discovery Sector Heats Up: ChinaAMC Hang Seng Biotech (03069) Rises Over 4% Intraday, ChinaAMC Innovative Drugs (03525) Gains Over 3% in Afternoon Session
Stock News  ·  09-30
AI Drug Discovery Sector Heats Up: ChinaAMC Hang Seng Biotech (03069) Rises Over 4% Intraday, ChinaAMC Innovative Drugs (03525) Gains Over 3% in Afternoon Session
Hong Kong Pharma Stocks Defy Market Slump as AI Drug Discovery Leads; GenScript Surges Over 9% to New High, Hang Seng Healthcare ETF Huabao (159137) Underlying Index Rises Over 2%
Deep News  ·  09-30
Hong Kong Pharma Stocks Defy Market Slump as AI Drug Discovery Leads; GenScript Surges Over 9% to New High, Hang Seng Healthcare ETF Huabao (159137) Underlying Index Rises Over 2%
CSPC Pharma Shares Rise Nearly 6% on String of R&D Updates Spanning mRNA Cancer Vaccines and Recombinant Protein Vaccines
Stock News  ·  09-30
CSPC Pharma Shares Rise Nearly 6% on String of R&D Updates Spanning mRNA Cancer Vaccines and Recombinant Protein Vaccines
Behind the Surge in BD Deals: Decoding the Differentiated Advantages of China's Innovative Drugs
Deep News  ·  09-30
Behind the Surge in BD Deals: Decoding the Differentiated Advantages of China's Innovative Drugs
CSPC Hits 5-Week High on US FDA's Nod on Herpes Zoster Vaccine Trial
Reuters  ·  09-30
CSPC Hits 5-Week High on US FDA's Nod on Herpes Zoster Vaccine Trial
Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal
Deep News  ·  09-29
Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal

Introduction

Company Name.
KraneShares MSCI All China Health Care Index ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.
Issue price:
--